Mesoblast Limited (MESO) fair value analysis
Nasdaq · Updated 2026-10-19
MESO price how computed
Valuation status
Awaiting full valuationMESO's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once MESO's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $13.28
- Sector
- Healthcare
- 12-month range
- $13.19–$20.96
- Market cap
- $1.72B
- From 52-week high
- -36.6%
- Shares outstanding
- 130M
- Rank in Healthcare by quality score
- #105 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Mesoblast Limited is a biotechnology company that develops cell-based medicines and regenerative medicine therapies for various diseases and conditions. The company operates globally with research and development activities based in Australia and the United States.
MESO currently ranks #105 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.72B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $120M
- Net margin
- -47.8%
- EPS (TTM)
- $-0.11
- Gross margin
- 143.2%
- Debt / equity
- 0.22
- Revenue growth (3-yr avg)
- 644.6%
- Shares outstanding
- 130M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 37 · neutral
- 50-day average
- $15.63
- 200-day average
- $15.69
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-03 ▲ beat (+100.0%)
2025-09 ▲ beat (+30.0%)
2025-06 ▲ beat (+90.0%)
2025-03 ▲ beat (+100.0%)
2024-12 ▲ beat (+90.2%)
2024-09 ▲ beat (+9.7%)
2024-03 ▲ beat (+100.0%)
2023-12 ▲ beat (+100.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 0 hold · 0 sell (3 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $37
- Target vs last price
- +178.6%
What our data shows for MESO
- Shares are trading in the lower third of their 12-month price range of $13.19–$20.96.
- The 14-day relative strength index sits at a neutral 37.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MESO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MESO news
TickrTrends' derived news-sentiment signal for MESO is currently mixed, computed from recent coverage.
- Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain (NASDAQ:MESO) (seekingalpha.com, 2026-10-19)
- Mesoblast GAAP EPS of -$0.04 beats by $0.08, revenue of $120.25M misses by $65.62M (NASDAQ:MESO) (seekingalpha.com, 2026-10-14)
- Mesoblast Gets FDA Approval For New Potency Assay, Stock Up In Pre-Market (rttnews.com, 2026-09-24)
More MESO news
- Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-27)
- Full Year 2026 Mesoblast Limited Earnings Presentation Transcript (gurufocus.com, 2026-08-27)
What people are saying
Follow the MESO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — MESO's 50/200-day trend state has shifted from mixed to downtrend this week, indicating a change in the company's recent momentum trajectory within the Healthcare sector. The valuation assessment remains classified as awaiting full valuation, meaning a complete determination of fair value has not yet been established based on available analysis.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MESO stock undervalued?
MESO's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is MESO's TickrTrends verdict?
MESO is currently marked 'Awaiting full valuation' - a verdict publishes automatically once MESO's own trailing P/E history validates under our standards.
How does MESO compare to other Healthcare stocks?
MESO ranks #105 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MESO overbought or oversold?
MESO's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does MESO usually beat earnings estimates?
Over its last 8 reported quarters MESO beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MESO?
Of 3 analysts covering MESO, 3 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $37 (+178.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.